Vertical: HealthcareBase Year: 2024
Market Size (2024)
$1.08B
Projected (2035)
$2.37B
CAGR (2019–2035)
6.1%
Key Players
10+
This report covers Vietnam Oncology Drugs Market with forecasts from 2019 to 2035. 10 key companies are profiled.
The Vietnam Oncology Drugs Market market is projected to grow at a CAGR of 6.1% from 2019 to 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Vietnam oncology drugs market is witnessing dynamic growth driven by multiple interrelated factors shaping both demand and supply sides. Rising cancer prevalence, fueled by aging demographics, lifestyle transitions, and environmental factors, increases the need for early diagnosis and effective treatments, propelling demand for oncology pharmaceuticals. Healthcare reforms by the government, including expanded health insurance coverage and investments in oncology centers, are improving patient access to advanced cancer therapies such as chemotherapy, targeted drugs, immunotherapies, and biologics.
Pharmaceutical companies, both domestic and multinational, are capitalizing on improving regulatory pathways and faster drug approvals, enabling broader availability of innovative therapies. Strategic collaborations between local distributors and global manufacturers also ensure a diverse portfolio of oncology medications in Vietnamese healthcare facilities. The rising middle class and awareness about early cancer detection further amplify demand for specialized medicines, contributing to market expansion.
On the supply side, Vietnam's pharmaceutical industry is undergoing transformation with increasing focus on self-sufficiency through domestic drug production and reducing import dependency, supported by government initiatives and favorable policies. Production capabilities certified with WHO-GMP and EU-GMP standards are expanding, thereby improving manufacturing quality and competitiveness.
However, market development is influenced by infrastructural disparities, with advanced oncology services concentrated in urban centers while rural areas face access challenges. Pricing and reimbursement complexities, as well as regulatory stringency, present ongoing challenges alongside the opportunity presented by biosimilars and affordable generics.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2024
Historical Period
2019 – 2023
Forecast Period
2025 – 2035
Primary Interviews
150+
Historical data (2019–2024) and forecast period (2024–2035)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Vietnam Oncology Drugs Market covering market dynamics, competitive landscape, and strategic outlook.
The Vietnam Oncology Drugs Market market is projected to reach $2.37B by 2035, growing at 6.1% CAGR. The Injectable segment holds the largest share.
Introduction
The Vietnam oncology drugs market is witnessing dynamic growth driven by multiple interrelated factors shaping both demand and supply sides. Rising cancer prevalence, fueled by aging demographics, lifestyle transitions, and environmental factors, increases the need for early diagnosis and effective treatments, propelling demand for oncology pharmaceuticals. Healthcare reforms by the government, including expanded health insurance coverage and investments in oncology centers, are improving patient access to advanced cancer therapies such as chemotherapy, targeted drugs, immunotherapies, and biologics.
Pharmaceutical companies, both domestic and multinational, are capitalizing on improving regulatory pathways and faster drug approvals, enabling broader availability of innovative therapies. Strategic collaborations between local distributors and global manufacturers also ensure a diverse portfolio of oncology medications in Vietnamese healthcare facilities. The rising middle class and awareness about early cancer detection further amplify demand for specialized medicines, contributing to market expansion.
On the supply side, Vietnam's pharmaceutical industry is undergoing transformation with increasing focus on self-sufficiency through domestic drug production and reducing import dependency, supported by government initiatives and favorable policies. Production capabilities certified with WHO-GMP and EU-GMP standards are expanding, thereby improving manufacturing quality and competitiveness.
However, market development is influenced by infrastructural disparities, with advanced oncology services concentrated in urban centers while rural areas face access challenges. Pricing and reimbursement complexities, as well as regulatory stringency, present ongoing challenges alongside the opportunity presented by biosimilars and affordable generics.
Rising cancer incidence & prevalence
According to the Global Cancer Observatory (IARC/WHO) and recent population-based cancer registries in Hanoi and Ho Chi Minh City, Vietnam is projected to experience more than 180,400 new cancer cases and over 120,000 cancer-related deaths annually in 2025 a figure that has nearly tripled since the 1990s. This surge is largely attributed to demographic shifts, lifestyle changes, and increased longevity across the nation.
For example, in Hanoi and Ho Chi Minh City the nation’s two most populous urban centers cancer incidence rose sharply from 28,506 cases in 2020 to a projected 36,333 cases in 2025, with lung, colorectal, breast, thyroid, and liver cancers representing 67% of all new diagnoses. Among men, lung cancer prevalence is especially high, while breast and thyroid cancers are notably common among women. Younger populations are increasingly affected as risk factors such as tobacco use, urban pollution, sedentary lifestyle, and dietary habits gain prevalence in contemporary society. Urban centers display some of the country’s highest incidence rates, but virtually all regions report climbing numbers, requiring urgent expansion of oncology services.
The real-world impact of these trends is reflected in hospital oncology wards, where continuous patient loads strain medical infrastructure and demand for advanced therapies accelerates. For instance, the age-standardized rate for breast cancer more than doubled, rising from 15.2 per 100,000 women in 1991 to over 40 per 100,000 in 2020, and is still increasing. This mounting burden compels a consistent upgrade in oncology drugs supply, regulatory support for expedited therapy approvals, and investments in healthcare services that enable the timely procurement and deployment of new cancer treatments throughout Vietnam.
Vietnam Oncology Drugs MARKET: Vietnam cancer Statistics at a glance, 2022
Category
Males
Females
Both sexes
Population
Incidence
Number of new cancer cases
Age-standardized incidence rate
Risk of developing cancer before the age of 75 years (cum. risk %)
Top 3 leading cancers (ranked by cases)
Liver
Lung
Stomach
Breast
Lung
Colorectum
Breast
Liver
Lung
Mortality
Number of cancer deaths
Age-standardized mortality rate
Risk of dying from cancer before the age of 75 years (cum. risk %)
Top 3 leading cancers (ranked by deaths)
Liver, Lung, Stomach
Breast, Lung, Liver
Liver, Lung, Stomach
Prevalence
5-year prevalent cases
Expanding health insurance coverage & reimbursement reforms
By May 2025, Vietnam’s health insurance coverage reached an unprecedented 96.5% of the population about 97 million residents—well ahead of the national target set for 2025. This near-universal coverage includes patients from diverse socioeconomic backgrounds, ensuring that even the poor and vulnerable have access to high-cost oncology treatments.
Vietnam's Ministry of Health has made comprehensive reforms to reimbursement policies, culminating in the amended Law on Health Insurance and new circulars that took effect in January 2025. These reforms guarantee that health insurance participants are now entitled to 100% coverage for medical examinations and inpatient treatments at both basic and specialized hospitals including cancer centers regardless of administrative boundaries or referral facilities. Rare and critical illnesses, such as cancer, are allowed direct access to high-level hospitals without complex referral procedures, addressing previous gaps in care delivery for urgent cases.
In practice, oncology patients benefit from standardized reimbursement rates of 80%, 95%, or even 100% for most anticancer drugs and services, depending on status and income bracket. For breast cancer, for instance, the majority of drugs are included in social health insurance reimbursement, dramatically lowering out-of-pocket payments, which previously caused catastrophic health expenditures for over 65% of cancer-affected households. Special policy groups such as the poor, near-poor, ethnic minorities, war veterans, and children qualify for zero or minimal co-payments, further inclusive measures that widen drug access.
With millions of annual healthcare visits funded by the insurance system and tens of thousands of oncology cases treated at major hospitals, these reforms actively drive demand for registered oncology drugs, increase market volumes for specialty therapies, and improve health outcomes across Vietnam.
Rapid growth of Vietnam’s pharma & biopharma market
Rapid growth in Vietnam’s pharmaceutical and biopharma sectors strongly drives demand and innovation within the oncology drugs market, as evidenced by official industry data and health policy reports. This market growth is powered by expansive public health spending, a population exceeding 100 million, and a steady increase in chronic disease burden including cancer as the country’s life expectancy and urbanization rates continue to rise.
Vietnam now boasts over 238 pharmaceutical manufacturing facilities certified to international WHO-GMP quality standards and 17 sites meeting the more stringent EU-GMP requirements, a leap from earlier decades when most drugs were imported. Additionally, more than 5,000 wholesalers and 62,000 retail outlets ensure broad access and robust distribution networks for oncology and other prescription drugs. In 2024, the nation imported roughly $4.4 billion in pharmaceuticals, a near 28% increase over the previous year, with France, Germany, the US, and India ranking among its biggest suppliers of novel drugs and biotherapeutics.
A crucial policy milestone is the National Strategy for Pharmaceutical Development (to 2030, vision to 2045), which aims to prioritize domestic drug research, enhance technology transfer, and support manufacturing of originator oncology drugs and advanced biopharma products. This includes new incentives for contract manufacturing, technology partnerships, and clinical trials, fast-tracking the introduction of innovative therapies for cancer into the local health system.
With upgraded infrastructure, streamlined logistics, and preferential trade agreements (such as the EU-Vietnam Free Trade Agreement, which renders 51% of European drugs tariff-free), Vietnam’s thriving pharma sector intensifies the supply and diversity of oncology drugs. Public hospitals accounting for about 65% of total pharmaceutical revenue are quickly adopting new cancer medicines and biopharma therapies, further fueling market growth and improving outcomes for cancer patients nationwide.
Improving clinical-trial capacity / regulatory modernization
Vietnam’s Ministry of Health has developed a rigorous, internationally harmonized regulatory framework for clinical trials, with processes now leveraging digital submissions, accelerated approvals, and alignment with ICH-GCP (International Council for Harmonisation Good Clinical Practice) standards. As of late 2024, Vietnam hosted over 721 registered clinical trials, with more than 82% classified as interventional and Phase III trials accounting for the largest share an indicator of increasing complexity, global collaboration, and readiness to evaluate novel oncology therapies.
Demand for cancer trials is particularly strong, driven by Vietnam’s substantial cancer burden (an estimated 180,400 new cases and 120,184 cancer deaths annually in 2022, according to GLOBOCAN IARC), which makes oncology a primary focus for both multinational pharmaceuticals and domestic players seeking real-world efficacy evidence before regulatory approval.
Local manufacturing / tech transfer
Local manufacturing and technology transfer present significant opportunities for the Vietnam oncology drugs market by enabling increased self-sufficiency, reduction of import dependency, and greater access to high-quality cancer therapies. Vietnam’s National Strategy for Developing the Pharmaceutical Industry to 2030 (Vision 2045) specifically targets technology transfer for at least 100 original pharmaceuticals, vaccines, and biological products, aspiring for domestic drugs to cover 80% of market volume and 70% of market value by 2030.
Leading policy reforms and investments such as the construction of Imexpharm’s new $58 million plant with 146 R&D projects, and AstraZeneca’s recent $100 million commitment underscore growing capacity for innovation and biologics production at home. The opening of a large-scale pharmaceutical-biological park in Thai Binh province (investment VND 3.8 trillion) reflects Vietnam’s strategic priority to enter advanced manufacturing, especially for biopharmaceuticals, biosimilars, and cancer therapeutics, breaking new ground away from reliance on chemical generics.
As of 2025, Vietnam operates 238 pharmaceutical factories certified with WHO-GMP and 17 with EU-GMP standards. Most transfers have focused on conventional biologics, but the regulatory environment is evolving to encourage local production of high-value oncology drugs, including incentives for tax, R&D, licensing, and preferential procurement policies for drugs clinically trialled and manufactured domestically. Recent legal changes to the Law on Pharmacy further streamline approvals for originator drugs and biosimilars, enhancing market entry for new therapies produced under tech transfer agreements.
For example, the Russian pharmaceutical company Medsintez and Vietnam's VNVC Vaccine and Biopharmaceutical Manufacturing Plant signed a comprehensive technology transfer agreement to produce biopharmaceuticals and advanced drugs in Vietnam, expanding domestic capabilities for oncology and vaccine manufacturing. This is expected to not only improve access and affordability for cancer patients but also elevate Vietnam's competitiveness in regional and global pharmaceutical supply chains.
Public–private partnerships & capacity building
Vietnam’s Ministry of Health is actively leveraging PPPs to connect governmental capacity with private sector expertise and funding, following national mandates and regulatory frameworks such as the 2020 PPP Law. Over the past two decades, Vietnam has signed 336 PPP contracts in health and related sectors, helping bridge funding, infrastructure, and service gaps.
For instance, high-profile PPPs involving Novartis and AstraZeneca have resulted in enhanced capacity for healthcare worker training, infrastructure upgrades, diagnostic technology access, and expansion of primary and specialty care models for non-communicable diseases, including oncology. Novartis’s partnership with the Ministry of Health demonstrates this through initiatives that provide diagnostics, affordable medicines, and advanced training for rural health staff, directly addressing workforce and access inequities in cancer management.
On the technological front, Vietnamese tech giants such as FPT have teamed with global pharmaceutical leaders to plan AI-powered clinical trials, digital health solutions, and rapid drug discovery platforms projects made feasible by PPP models and Vietnam’s tech talent pool, which is set to exceed one million IT specialists by 2030. These collaborative efforts drastically reduce the cost and time associated with new drug development and enable remote, data-driven cancer care.
Additionally, PPPs facilitate infrastructure development for cancer hospitals, public screening initiatives, and “beyond-the-pill” support services such as home nursing and tele-oncology, enhancing the comprehensiveness and holistic nature of cancer services. Such joint efforts are crucial in addressing Vietnam’s disparities in care quality and regional access, while building a sustainable market for advanced oncology drugs and innovation-driven treatment models.
Biosimilars & affordable generics
Biosimilars and affordable generics present a major opportunity for Vietnam’s oncology drugs market by addressing the pressing need for cost-effective cancer therapies while supporting broader access for all patient groups. With cancer drug costs being a major financial challenge, Vietnam’s regulatory authorities have moved to simplify and accelerate the approval of biosimilars and generic oncology drugs. The Ministry of Health’s Circular No. 12/2025/TT-BYT, effective from July 1, 2025, introduces a more principles-based approach to drug classification and registration, mandating that biosimilars meet rigorous bioequivalence and safety criteria before local approval. Vietnam’s new framework is also aligned with international standards, accepting registration dossiers based on prior approval in countries with Stringent Regulatory Authorities (e.g., EMA, FDA), which streamlines market entry for affordable versions of high-cost biologics.
Biosimilars biologic drugs shown to be highly similar to already-approved originators offer significant price reductions compared to innovator biologics, making treatments like trastuzumab, bevacizumab, or rituximab far more accessible to Vietnamese cancer patients. Regulatory changes also encourage domestic and foreign manufacturers to engage in technology transfer and contract manufacturing for biosimilars and generics, with several Vietnamese companies already registering affordable oncology biosimilars and expanding capacity under government-supported initiatives.
For example, collaborative programs between academic hospitals and global pharmaceutical partners have provided professional training for over 250 oncology specialists and pharmacists in biosimilar therapy assessment and use, ensuring quality and safety in clinical applications. These educational initiatives, backed by both the Vietnam Cancer Association and international organizations, support physician acceptance and appropriate prescribing of biosimilars, which remains critical to widespread uptake.
Proliferation of Counterfeit and Substandard Drugs
The Drug Administration of Vietnam has repeatedly warned about the presence of fake cancer drugs in the market, reporting cases where these counterfeit medicines, lacking active ingredients or containing harmful substances, have been distributed widely through pharmacies and hospitals. For instance, a notorious scandal involving VN Pharma saw over 600,000 boxes of counterfeit cancer drugs sold illegally, generating illicit profits of around VND 31.5 billion and endangering thousands of patients.
Statistics show that in 2023 alone, Vietnamese authorities detected over 160 cases related to counterfeit drug production and trafficking, leading to arrests and sanctions. In Ho Chi Minh City, a major hotspot for counterfeit pharmaceuticals, the number of seized counterfeit samples rose from 5 in 2022 to 40 in 2024, with many lacking the proper active ingredients or being adulterated with synthetic drugs. This alarming trend complicates effective cancer management because counterfeit drugs fail to deliver therapeutic benefits, allowing disease progression and resistance development.
Counterfeiters employ increasingly sophisticated methods such as fake QR codes, forged labels, and mixing genuine with fake drugs—making detection difficult even for regulators and healthcare professionals. Though hospitals reportedly avoid counterfeit drugs by ensuring clear provenance, these illicit products continue circulating in less regulated channels, including online platforms and informal markets.
The consequences of counterfeit oncology drugs include delayed treatment, increased mortality risk, and eroded confidence in Vietnam’s pharmaceutical system.
Dependence on Imports for High-Value Biologics
Dependence on imports for high-value biologics remains a critical restraint for Vietnam’s oncology drugs market, creating supply vulnerabilities, affordability challenges, and access barriers for advanced cancer therapies. While Vietnam’s domestic pharmaceutical industry has made progress in generic drug manufacturing, it still faces major hurdles in producing complex biologics largely due to high technological requirements, limited R&D, and a shortage of skilled biomanufacturing personnel.
Over 90% of raw pharmaceutical ingredients are imported, with more than half sourced from mainland China, reinforcing the country’s reliance on global supply chains for raw materials and finished biologic drugs used in oncology. Leading therapies including monoclonal antibodies, checkpoint inhibitors, and targeted biologics crucial to the treatment of cancers like breast, lung, and lymphoma are supplied primarily by international companies such as Roche, Novartis, and Pfizer, due to the absence of domestic alternatives. This import dependence means that any disruption such as trade tensions, COVID-19-related delays, or currency fluctuations can quickly result in shortages and price spikes that hit both hospitals and patients.
Vietnamese authorities have recognized these risks: national strategies now aim to boost local biopharma capacity so that by 2030, 80% of essential drugs are produced domestically, yet progress in biologics remains slow. Regulatory frameworks for technology transfer and biosimilar approvals have been introduced, but local firms still lag behind in the necessary quality standards (i.e., EU GMP, PIC/S GMP) for biologics manufacturing. Recent attempts at “fill-finish” processing where import biologics are packaged locally offer limited cost relief but do not address production or innovation gaps.
The practical impact is clear, many cancer patients depend on expensive imported biologic medicines, with costs frequently exceeding annual incomes and limited insurance reimbursement.
Uneven access across regions
Comprehensive cancer care including advanced diagnostics like PET/CT, radiotherapy, specialist consultations, and access to the latest oncology drugs is concentrated in a handful of major hospitals in Ho Chi Minh City, Hanoi, and other larger provinces. As of the In 2016 data, only three comprehensive cancer centers and 45 oncology departments exist nationwide, and 2010 survey stating that 10 of 63 provincial hospitals cannot offer any cancer services at all.
Access to degree-qualified pharmacists and regulated drug outlets is also dramatically better in urban centers; in rural and poor districts, many outlets lack registered staff and appropriate oversight, raising concerns about the quality and safety of medicines, including oncology drugs. Even with an average of 102 drug outlets per 100,000 people among the highest densities in Vietnam, pharmacies in remote areas may be poorly stocked or rely on non-specialist staff, exacerbating inequities.
Modern radiotherapy and nuclear medicine equipment shortages further limit timely treatment for cancer patients outside metropolitan regions. Hospital overcrowding is endemic; in leading urban cancer hospitals, bed occupancy often exceeds 150%, while patients from remote areas are forced to travel long distances and wait weeks or months for appointments and specialized therapies. In fact, 70–80% of cancer patients in Vietnam present at late stages due to poor access to screening and early intervention services, with provincial cancer capacity estimated to only meet 30–40% of actual demand.
The gap in cancer care infrastructure means rural and economically disadvantaged groups have delayed, incomplete, or even unaffordable access to effective oncology drugs and treatments hindering equitable cancer outcomes nationwide.
Reimbursement complexity and pricing negotiations
Vietnam’s health insurance system, covering over 93.4% of the population as of 2024, operates under a complex drug reimbursement framework regulated by the Ministry of Health’s Circular No. 37/2024/TT-BYT, effective from January 1, 2025. This circular establishes detailed principles and criteria for drug inclusion on the reimbursement list, considering treatment cost, clinical efficacy, and budget impact assessments, but also introduces multi-layered administrative procedures requiring extensive documentation and negotiations for price and reimbursement rates.
Pricing negotiations for oncology drugs are often protracted due to high costs and the need for balancing innovation incentives with public affordability. Drugs like trastuzumab used for HER2-positive breast cancer receive partial reimbursement with rates between 48-60%, while others such as pertuzumab are not yet covered under social health insurance, forcing patients to bear out-of-pocket costs that can exceed their annual income. This reimbursement gap means many patients must decide between expensive life-saving therapies and financial hardship.
The fragmented nature of reimbursement coverage further complicates access, as some innovative immunotherapies and targeted therapies remain excluded from the basic social health insurance package, relying instead on private insurance or out-of-pocket payments. While private insurance providers add some flexibility, their uptake remains limited, and reimbursement limits can cap payments at lower levels. Additionally, Vietnam’s nascent Health Technology Assessment (HTA) system, crucial for evidence-based pricing decisions, is still developing, resulting in slower assessments and delays in drug listing.
These complexities extend to administrative burdens on providers and pharmaceutical companies, with frequent policy updates requiring continuous adaptation.
Stringent government regulations
With the implementation of Circular No. 12/2025/TT-BYT by the Ministry of Health in July 2025, drug registration requirements underwent significant revision to align more closely with international standards while maintaining rigorous safety and efficacy assessments.
Although this newer framework offers some regulatory streamlining—like accepting a single Certificate of Pharmaceutical Product (CPP) from a Stringent Regulatory Authority (SRA) country and requiring submission of Vietnamese registration applications within five years after approval by SRAs it also introduces strict limits on supplemental dossier rounds, reducing the opportunities to address deficiencies to two rounds unless critical issues arise. This restricts flexibility for manufacturers and heightens pressure to prepare entirely compliant applications upfront.
Moreover, compliance with evolving pharmaceutical laws, such as Law No. 44/2024/QH15 effective July 2025, mandates adherence to quality standards akin to EU-GMP and Japanese GMP standards that few local producers currently meet. These regulatory burdens mean that many domestic firms face high costs upgrading manufacturing and quality assurance systems, constraining their ability to compete with imports or scale production of innovative oncology biologics and biosimilars.
Furthermore, regulations tightly control drug pricing, advertising content, and shelf-life requirements at customs clearance, adding layers of administrative complexity. While intended to protect public health and ensure quality, these policies increase market entry barriers for new oncology drugs, delay patient access, and complicate strategic partnerships and technology transfers critical for market development.
While Vietnam’s government regulations are modernizing and internationalizing, their stringency involves operational, financial, and procedural challenges that require pharmaceutical companies to invest heavily in compliance and quality, posing a restraint on the rapid availability and affordability of new oncology drugs in the Vietnamese market.
industry trend analysis
Regulatory Environment & Compliance
The regulatory landscape for the oncology drug market in Vietnam is evolving rapidly, driven by the government’s efforts to streamline processes and align with international standards. The Ministry of Health (MOH) serves as the primary regulatory authority, with the Drug Administration of Vietnam (DAV), a division under the MOH, holding comprehensive responsibility for the registration, licensing, and market entry of pharmaceutical products, including oncology drugs.
In recent years, Vietnam has significantly improved its regulatory framework for clinical trials, with approval timelines now averaging 4–6 months, substantially faster than many other Southeast Asian nations. This efficiency is supported by Vietnam’s adherence to Good Clinical Practice (GCP) and International Council for Harmonisation (ICH) guidelines, ensuring the quality, safety, and efficacy of oncology trials.
DAV evaluates oncology drug submissions based on clinical trial data and requires detailed disclosures regarding drug composition, manufacturing processes, and packaging.
The National Institute of Drug Quality Control (NIDQC), another key player, conducts rigorous quality testing and post-market surveillance, especially for oncology medications, to ensure compliance with national standards.
Reimbursement and usage decisions for cancer therapies fall under the purview of the MOH, which manages the national essential drug list and provides access to certain oncology treatments through public healthcare programs, sometimes at no or reduced cost.
Patients not covered by government programs may access treatments through private insurance schemes.
In a move toward global regulatory alignment, DAV has increasingly adopted international standards such as the ICH guidelines and the PIC/S GMP (Pharmaceutical Inspection Co-operation Scheme – Good Manufacturing Practice) requirements, positioning Vietnam as a compliance-driven market. The regulatory process saw a major shift in October 2022 with the issuance of Circular 08/2022/TT-BYT, which introduced a more efficient and transparent drug registration system. Key reforms include a simplified dossier format, a shortened review timeline, and the launch of an online application platform.
However, the new system also introduces more stringent documentation requirements, such as a Certificate of Pharmaceutical Product (CPP) from the EMA or other Stringent Regulatory Authorities, and legal GMP-compliance documents for raw material and component manufacturers. These reforms reflect Vietnam's ambition to become a trusted global regulatory environment while still requiring careful navigation of local specifics for successful market entry.
market Trends & Innovation
The Vietnam oncology drug market is poised for transformation as global advancements in cancer care begin to influence local healthcare practices. A growing cancer burden, combined with a maturing regulatory environment and improving healthcare infrastructure, is setting the stage for major shifts in how oncology is practiced and how treatments are developed, approved, and delivered. Several key trends and innovations are beginning to reshape the landscape of oncology in Vietnam.
Advances in Drug Development and the Oncology Pipeline
Vietnam is seeing increased access to cutting-edge oncology drugs, especially with the entry of multinational pharmaceutical companies offering targeted therapies, biologics, and immuno-oncology treatments. There is a growing interest in checkpoint inhibitors and CAR-T cell therapies, which are being introduced in Vietnam through expanded access programs or conditional registration.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 108 companies operating in the Vietnam Oncology Drugs Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
3 interactive charts drawn from the Vietnam Oncology Drugs Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
